So-Young International Inc. SY PHARMA
Company Overview
So-Young International Inc. operates an online platform for consumption healthcare services in the People's Republic of China. The company offers So-Young Mobile App that offers users access to medical aesthetic knowledge, community support and reservation options for treatment with medical professionals, and medical aesthetic institutions; Weixin mini program to explore treatment options, check prices, schedule appointments, participate in online consultations, and track follow-ups; and medical aesthetic community content through its website soyoung.com. Its aesthetic centers offer non-invasive to minimally invasive procedures, including device-based options, such as thread lifts, intense pulsed light, ultrasound facelifts, picosecond lasers, and body contouring treatments, as well as injectable treatments, including skin boosters, hyaluronic acid-based products, botox, and type I and type III collagen. In addition, the company engages in the research and development, production, sale, and distribution of light therapy devices, including excimer laser systems, UV excimer therapy devices, LED and red-light therapy systems, and advanced laser and intense pulsed light technologies; surgical laser devices, including carbon dioxide laser machines, multi-wavelength and semiconductor laser systems for urological treatments, and hydrodynamic-assisted liposuction systems for plastic surgery, as well as pneumatic liquid spray devices skin cleansing. Further, it offers injectable products; sales and technical, maintenance, installation, operational training, error reporting, maintenance, and equipment packaging services; consumption healthcare services, including dermatology, dentistry and orthodontics, physical examinations, gynecology, and postnatal care; reservation services; and content management through beauty diaries, short-form videos, treatment reviews, featured articles, and chat messages. The company was founded in 2013 and is headquartered in Beijing, China.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.24.
Recent Developments
- Dec 2025 Revenue of $1.52B (+3.9% YoY); net profit $-242.30M.
- Trailing 12 Months Year-on-year growth — revenue +45.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 6.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 6.59% |
| 1 Year: | 45.60% |
Stock Price Performance
| 1 Year: | -48.04% |
| 6 Months: | -14.24% |
| 3 Months: | +44.81% |
| 1 Month: | +21.56% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)60.85 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 48.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SY So-Young International Inc. PHARMA | 2.65 | -7.36 | $225.29M | 0.00% | -14.28% | -15.04% | 6.59% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 297.27M | 378.75M | 386.67M | 460.72M | 432.77M |
| Cost of Revenue | 151.41M | 184.56M | 203.80M | 255.95M | 251.00M |
| Gross Profit | 145.85M | 194.19M | 182.87M | 204.77M | 181.78M |
| Operating Expenses | 189.27M | 241.30M | 255.58M | 308.01M | 239.67M |
| Operating Income | -43.41M | -47.11M | -72.71M | -103.23M | -57.89M |
| EBITDA | -43.41M | -47.11M | -72.71M | -103.23M | -57.89M |
| Interest Expense | - | - | - | - | - |
| Pretax Income | -34.76M | -32.92M | -63.70M | -114.73M | -50.96M |
| Tax Provision | -1.60M | 1.88M | 1.14M | -619.00K | -753.00K |
| Net Income | -33.14M | -36.04M | -64.28M | -108.85M | -49.18M |
| Diluted EPS | -0.32 | -0.35 | -0.64 | -1.08 | -0.48 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 1.26B | 1.50B | 1.47B | 1.52B |
| Cost of Revenue | - | 393.29M | 544.34M | 567.59M | 795.72M |
| Gross Profit | - | 864.58M | 953.69M | 899.11M | 727.69M |
| Operating Expenses | - | 967.39M | 1.01B | 983.60M | 994.15M |
| Operating Income | - | -102.81M | -61.05M | -84.48M | -266.47M |
| EBITDA | - | -55.72M | -14.96M | -38.56M | -209.25M |
| Interest Expense | - | - | - | - | - |
| Pretax Income | - | -87.07M | 7.87M | -588.09M | -246.11M |
| Tax Provision | - | -20.96M | -18.07M | -905.00K | 796.00K |
| Net Income | - | -65.55M | 21.28M | -589.53M | -242.30M |
| Diluted EPS | - | -0.61 | 0.21 | -5.72 | -2.39 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 3.20B | 3.21B | 2.74B | 2.65B |
| Current Assets | - | 1.92B | 1.72B | 1.72B | 1.48B |
| Cash & Equivalents | - | 694.42M | 426.12M | 587.75M | 418.21M |
| Inventory | - | 120.48M | 118.92M | 151.75M | 233.39M |
| Receivables | - | 36.01M | 57.22M | 98.77M | 51.53M |
| Total Liabilities | - | 590.00M | 653.25M | 776.43M | 980.82M |
| Current Liabilities | - | 538.04M | 540.42M | 630.21M | 784.05M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 71.26M | 145.77M | 239.88M | 299.71M |
| Total Equity | - | 2.50B | 2.44B | 1.84B | 1.55B |
| Shares Outstanding | - | 85.07M | 85.69M | 89.90M | 91.02M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -112.87M | 22.50M | -25.63M | -105.39M |
| Investing Cash Flow | - | -572.21M | -202.61M | 257.04M | -42.81M |
| Financing Cash Flow | - | -13.59M | -100.02M | -21.51M | -63.70M |
| Capital Expenditure | - | -15.71M | -51.18M | -62.55M | -196.62M |
| Free Cash Flow | - | -128.58M | -28.68M | -88.18M | -302.01M |
| Net Change in Cash | - | -698.67M | -280.12M | 209.89M | -211.90M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 68.7% | 63.7% | 61.3% | 47.8% |
| Operating Margin % | - | -8.2% | -4.1% | -5.8% | -17.5% |
| Net Margin % | - | -5.2% | 1.4% | -40.2% | -15.9% |
| ROE % | - | -2.6% | 0.9% | -32.1% | -15.6% |
| ROCE % | - | -3.9% | -2.3% | -4.0% | -14.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | TB Alternative Assets Ltd. | 3.62% | 3.07M | $8.44M |
| 2 | Morgan Stanley | 1.45% | 1.23M | $3.39M |
| 3 | Barclays Plc | 1.33% | 1.13M | $3.11M |
| 4 | Citigroup Inc. | 1.22% | 1.04M | $2.85M |
| 5 | UBS Group AG | 0.53% | 446.55K | $1.23M |
| 6 | State Street Corporation | 0.46% | 390.95K | $1.08M |
| 7 | Dimensional Fund Advisors LP | 0.27% | 226.67K | $623.34K |
| 8 | Jane Street Group, LLC | 0.13% | 112.00K | $308.00K |
| 9 | Nomura Holdings Inc. | 0.13% | 107.20K | $294.80K |
| 10 | HRT Financial LP | 0.09% | 77.75K | $213.82K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SY
So-Young (SY) COO gets 28,203 options vesting on grant date - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxPbXFrNGpIMlN2RjNfWmZZeDJDTmNPYXZFOEkzTGppdG0tYjhsR1haUUJXUXBOMDNmTDBEaG0zcEhtRzNCeVdmdllsU0l6T2w5TkJJYmt5Z0RydklOaDRUelgxTHptbHQ1cTBLa1NJdmpzd2lydTRTVTNMTDY4R0cxeDRnaGlGR2tUczRJRT…
So-Young International (NASDAQ: SY) grants 7,051 low-priced options to its CMO - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxONk1ZNTkyOG9VbkFVbThhSW4wWTlSdmtTNldvZ1EzU1ZkZVRieElOandhRHBQbHlWOE1lV2paX3dDQjFrZ2o1TWhZemZ4aFF5dW1jc1Z3MVNLNmYxcGtVZjF4cEQxTl9wMGllWUV0SEhXRnF0Vlh1QXQ4Tk1tSGxfQzN1Wk5lQnFKSDlkaT…
SY Stock Moves As So-Young International Reshapes CFO Role - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMihgFBVV95cUxQdklZY29ZX3AwU3l5aTZQV0FSZ0p6My11dThveHBSTEVCbkFiZEMwak95TkdYV2FXYklrVmlmNkp6RGhnTWFIY01yRXpSUmRfMHplMzlCeVVLVUJNX0puRS1yeDdlS29uS3JJdkZBb0Nld1k3QUdrNUx6MmNUaUpEV1plLU91dw?oc=5" t…
SY Stock Jumps As So-Young Taps New CFO, Eyes Earnings - timothysykes.com
<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxOLVRVbXdWRlM0Mm1EeUxaZk15d2owU1V5TFMzQVJ3b0NxMTJxRVZFOGNVeDNvMXlmck5idDN0Zjd1VUVaV3NBblRvNGpwcHdmUTJGcWs4VHBZRFVUQXpQMVlMQmhfR2Rmajc2c1NaajA5RDdzZ3ZVdnVlMFpaSDBMYlhWNzg?oc=5" targ…
SY - Finviz
<a href="https://news.google.com/rss/articles/CBMiQ0FVX3lxTE5aVlF6Vm5XckRQTHFUN05wVWlybzI4Mk13c25jSlJRd2RUWDdzdlFyRXkyUHV5TDRydjNIQWxaNU1ESnc?oc=5" target="_blank">SY</a> <font color="#6f6f6f">Finviz</font>…
SO-YOUNG INTERNATIONAL Q1 2026 Earnings Preview: Recent $SY Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxNRjlUb2hkUDJ2TUNQa1U2TlVycklzUlgydHA0UG5ZSFdXOWxQSWo0R182dExfajAxbi1WbHROemJUeUNKYUQ0Tlg5anNQbG53aEhKdE1PX0VqU2p5VHZKdEFSSVBHaFdxcGhNbHFUdlJ3RWJRSHlnNHFOOU1GTkI3RFhVRk1XWXNtT2RVOW…
SY — Frequently Asked Questions
What is the current share price of So-Young International Inc. (SY)?
As of 2026-09-19 21:16 PDT, So-Young International Inc. (SY) trades at $2.65 on NasdaqCM. Its 52-week range is $1.32 to $5.10.
What is the market capitalisation of SY?
So-Young International Inc. (SY) has a market capitalisation of $225.29M on NasdaqCM.
What is the P/E ratio of SY?
SY trades at a trailing price-to-earnings (P/E) ratio of -7.36. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.24.
What is the return on equity (ROE) of SY?
SY has a return on equity (ROE) of -15.04%. Its return on capital employed (ROCE) is -14.28%.
Is SY a good stock to buy?
This page provides a data-driven analysis of So-Young International Inc. (SY), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.